Mitchell Capital Management Co. Raises Holdings in Amgen, Inc. (AMGN)

Mitchell Capital Management Co. boosted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 11.5% during the 3rd quarter, Holdings Channel reports. The firm owned 6,128 shares of the medical research company’s stock after purchasing an additional 630 shares during the period. Mitchell Capital Management Co.’s holdings in Amgen were worth $1,270,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Cedar Capital LLC purchased a new stake in shares of Amgen in the third quarter valued at about $279,000. Piedmont Investment Advisors Inc. lifted its stake in shares of Amgen by 39.8% in the third quarter. Piedmont Investment Advisors Inc. now owns 77,598 shares of the medical research company’s stock valued at $16,085,000 after purchasing an additional 22,078 shares during the period. Norinchukin Bank The lifted its stake in shares of Amgen by 6.1% in the third quarter. Norinchukin Bank The now owns 116,391 shares of the medical research company’s stock valued at $24,127,000 after purchasing an additional 6,696 shares during the period. Mckinley Capital Management LLC Delaware lifted its stake in shares of Amgen by 32.4% in the third quarter. Mckinley Capital Management LLC Delaware now owns 2,252 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 551 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Amgen by 131.2% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,717 shares of the medical research company’s stock valued at $978,000 after purchasing an additional 2,677 shares during the period. 77.91% of the stock is currently owned by institutional investors.

Shares of AMGN opened at $192.57 on Friday. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The stock has a market cap of $122.71 billion, a price-to-earnings ratio of 15.31, a price-to-earnings-growth ratio of 2.00 and a beta of 1.37. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.45 by $0.24. The company had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.27 earnings per share. As a group, research analysts anticipate that Amgen, Inc. will post 14.24 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s payout ratio is currently 41.97%.

Several analysts recently commented on AMGN shares. Oppenheimer reiterated a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research note on Tuesday, August 28th. Jefferies Financial Group reiterated a “buy” rating and issued a $220.00 price objective on shares of Amgen in a research note on Friday, August 24th. Cann reiterated a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research note on Monday, July 30th. BidaskClub upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Wednesday, September 26th. Finally, Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research note on Monday, October 1st. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $204.55.

TRADEMARK VIOLATION NOTICE: “Mitchell Capital Management Co. Raises Holdings in Amgen, Inc. (AMGN)” was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/25/mitchell-capital-management-co-raises-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply